Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Autoimmune Diseases
Biotech
Scipher picks up Chemomab’s liver disease drug via merger
Precision immunology company Scipher Medicine will absorb Chemomab after identifying the Israeli biotech’s liver disease drug as the ideal fit.
James Waldron
Jul 8, 2026 9:26am
Deerfield’s Boulevard Bio pens $1.6B deal for trispecific TCE
Jun 30, 2026 8:00am
Cabaletta's autoimmune CAR-T strategy is built on 'durability'
Jun 4, 2026 8:26am
Has Novartis’ T-Charge push been overtaken by in vivo CAR-Ts?
May 22, 2026 8:28am
Odyssey CEO sees $304M IPO creating ‘little large pharma’
May 8, 2026 7:27am
Kyverna’s full SPS data set stage for first autoimmune CAR-T nod
Apr 21, 2026 6:45pm
